ロード中...
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
BACKGROUND: Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to determine the efficacy and safety profile of eribulin and explore potential predictive factors for th...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8274129/ https://ncbi.nlm.nih.gov/pubmed/34290830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211030210 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|